Spironolactone use and renal toxicity: population based longitudinal analysis

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Spironolactone is a potassium-sparing diuretic used in heart failure management.
• The Randomised Aldactone Evaluation Study (RALES) significantly impacted spironolactone prescribing guidelines.
• Assessing the real-world safety of spironolactone post-RALES is crucial for clinical practice.

Purpose of the Study:

• To evaluate the safety of spironolactone prescribing within the UK National Health Service.
• To determine if increased spironolactone use correlates with adverse events like hyperkalemia.
• To assess spironolactone safety in both heart failure and non-heart failure populations.

Main Methods:

• A population-based longitudinal analysis was conducted using a record linkage database in Tayside, Scotland.
• Prescribing rates for spironolactone, hospital admissions for hyperkalemia, and outpatient hyperkalemia/renal function were analyzed.
• Data was compared before and after the publication of the RALES study results in 1999.

Main Results:

• Spironolactone prescriptions and serum potassium/creatinine measurements increased substantially post-RALES, in patients with and without heart failure.
• Hospital admissions for hyperkalemia remained low and did not increase over the study period.
• Outpatient hyperkalemia rates decreased despite increased spironolactone use, particularly in high-risk patients (e.g., those on ACE inhibitors with recent heart failure hospitalization).

Conclusions:

• Increased spironolactone use, even in non-heart failure patients, was not associated with a rise in hyperkalemia-related hospital admissions.
• Careful monitoring of patients on spironolactone appears effective in preventing hyperkalemia.
• The findings support the safe integration of spironolactone into routine clinical practice with appropriate patient surveillance.